首页> 外文期刊>Journal of Medicinal Chemistry >1-(3-Hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties
【24h】

1-(3-Hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties

机译:1-(3-羟基-1-金刚烷基)氨基乙酰基-2-氰基-(S)-吡咯烷:一种具有抗高血糖特性的强效、选择性和口服生物利用度的二肽基肽酶IV抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and structure-activity relationship of a new DPP-IV inhibitor class, N-substituted-glycyl-2-cyanopyrrolidines, are described as well as the path that led from clinical development compound 1-2-5-cyanopyridin-2-ylaminoethylaminoacetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728, 8c) to its follow-up, 1-3-hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine (NVP-LAF237, 12j). The pharmacological profile of 12j in obese Zucker fa/fa rats along with pharmacokinetic profile comparison of 8c and 12j in normal cynomolgus monkeys is discussed. The results suggest that 12j is a potent, stable, selective DPP-IV inhibitor possessing excellent oral bioavailability and potent antihyperglycemic activity with potential for once-a-day administration.
机译:二肽基肽酶 IV (DPP-IV) 抑制有可能成为 2 型糖尿病的宝贵疗法。描述了一种新的DPP-IV抑制剂类N-取代-甘氨酰-2-氰基吡咯烷的合成和构效关系,以及从临床开发化合物1-[2-[5-氰基吡啶-2-基]氨基]乙基氨基]乙酰基-2-氰基-(S)-吡咯烷(NVP-DPP728,8c)到其后续产品1-[[3-羟基-1-金刚烷基)氨基]乙酰基]-2-氰基-(S)-吡咯烷(NVP-LAF237,12j)的路径。讨论了12j在肥胖Zucker fa/fa大鼠中的药理学特征,以及8c和12j在正常食蟹猴中的药代动力学特征比较。结果表明,12j 是一种有效、稳定、选择性的 DPP-IV 抑制剂,具有出色的口服生物利用度和有效的抗高血糖活性,可每天给药一次。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号